{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:40:14Z","timestamp":1787496014806,"version":"build-2736575974"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,23]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) are often elevated in liver cancer, making it difficult to monitor for bacterial infection. Hence, it is tempting to use more bacterial-specific sepsis markers such as procalcitonin (PCT) during immunosuppressive chemotherapy. This case study highlights the challenges of interpreting clinical chemistry sepsis biomarkers in patients with advanced cholangiocarcinoma (CCA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 55-year-old man presented with a liver mass on routine ultrasonography. MRI and CT showed multiple liver and bone metastases. The immunohistochemistry findings were consistent with an adenocarcinoma of the pancreaticobiliary system. After the diagnosis of primary hepatic CCA (NTM stage IV; FGFR2-SHROOM3 translocation) and 14 months of chemotherapy, the patient developed progressive liver lesions and new lung metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses and interventions:<\/jats:title>\n                    <jats:p>During the last chemotherapy, PCT was highly elevated (&gt;100\u2009ng\/mL), usually observed in severe sepsis or septic shock, whereas CRP was moderately elevated (&lt;50\u2009mg\/L). The patient had mild leukopenia but no fever, systemic infection or septic shock. Blood and urine cultures were negative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>After referral to best supportive care, the patient died of liver failure. Retrospective blood analysis revealed high levels of soluble CD14 subtype, a bacterial sepsis marker known as presepsin. Calcitonin and IL-6 levels were above normal, consistent with advanced CCA, but not with a PCT\/calcitonin-secreting tumor or systemic inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Oncologists are aware that CRP and IL-6 values can be elevated in liver cancer. Here, we further demonstrate that highly elevated, septic shock-like PCT values can occur even in the absence of bacterial sepsis. In addition, presepsin may be elevated, although mechanistically unrelated to PCT. Therefore, sepsis markers should be interpreted with caution and in the clinical context, not only in patients with neuroendocrine or hepatocellular carcinoma, which are known to secrete PCT and calcitonin, but also in patients with advanced CCA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000042115","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:01:19Z","timestamp":1748304079000},"page":"e42115","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Highly elevated sepsis biomarkers in advanced cholangiocarcinoma without sepsis: A case report and literature review"],"prefix":"10.1097","volume":"104","author":[{"given":"Bianca","family":"Karnuth","sequence":"first","affiliation":[{"name":"Medizinisches Versorgungszentrum f\u00fcr Labormedizin und Mikrobiologie Ruhr GmbH, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9606-8217","authenticated-orcid":false,"given":"Almut","family":"Brundert","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Evangelische Kliniken Essen-Mitte gGmbH, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3601-3408","authenticated-orcid":false,"given":"Claus","family":"Langer","sequence":"additional","affiliation":[{"name":"Medizinisches Versorgungszentrum f\u00fcr Labormedizin und Mikrobiologie Ruhr GmbH, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9609-3405","authenticated-orcid":false,"given":"Thomas","family":"Masetto","sequence":"additional","affiliation":[{"name":"Institute of Molecular Medicine I, Medical Faculty, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"},{"name":"DiaSys Diagnostic Systems GmbH, Holzheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Evangelische Kliniken Essen-Mitte gGmbH, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"J\u00fcdt","sequence":"additional","affiliation":[{"name":"Institute of Molecular Medicine I, Medical Faculty, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2987-2991","authenticated-orcid":false,"given":"Yuriko","family":"Stiegler","sequence":"additional","affiliation":[{"name":"Medizinisches Versorgungszentrum f\u00fcr Labormedizin und Mikrobiologie Ruhr GmbH, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0889-895X","authenticated-orcid":false,"given":"Hugo","family":"Stiegler","sequence":"additional","affiliation":[{"name":"Medizinisches Versorgungszentrum f\u00fcr Labormedizin und Mikrobiologie Ruhr GmbH, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0048-2279","authenticated-orcid":false,"given":"Christoph","family":"Peter","sequence":"additional","affiliation":[{"name":"Institute of Molecular Medicine I, Medical Faculty, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2860-3391","authenticated-orcid":false,"given":"Matthias","family":"Grimmler","sequence":"additional","affiliation":[{"name":"Institute for Biomolecular Research, Hochschule Fresenius gGmbH, University of Applied Sciences, Idstein, Germany"},{"name":"DiaServe Laboratories GmbH, Iffeldorf, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma.","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma-evolving concepts and therapeutic strategies.","volume":"15","author":"Ilyas","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J Hepatol"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1515\/cclm-2018-0259","article-title":"Procalcitonin-guided antibiotic therapy: an expert consensus.","volume":"56","author":"Bartoletti","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1515\/cclm-2018-1347","article-title":"Sepsis biomarkers: past, present and future.","volume":"57","author":"Lippi","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1515\/cclm-2018-1181","article-title":"Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use.","volume":"57","author":"Schuetz","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.cmi.2014.12.026","article-title":"The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis.","volume":"21","author":"Hoeboer","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"R11-20250527","first-page":"6877","article-title":"Academy of emergency medicine and care-society of clinical biochemistry and clinical molecular biology consensus recommendations for clinical use of sepsis biomarkers in the emergency department.","volume":"13","author":"Lippi","year":"2017","journal-title":"Emerg Care J"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13104-018-3204-1","article-title":"Higher cut-off serum procalcitonin level for sepsis diagnosis in metastatic solid tumor patients.","volume":"11","author":"Aziz","year":"2018","journal-title":"BMC Res Notes"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"e21210","DOI":"10.1097\/MD.0000000000021210","article-title":"Elevated procalcitonin levels in primary hepatic neuroendocrine carcinoma: case report and literature review.","volume":"99","author":"Han","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/jgh.14568","article-title":"Hepatobiliary and pancreatic: a procalcitonin-secreting and calcitonin-secreting pancreatic neuroendocrine carcinoma.","volume":"34","author":"Takahashi","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1097\/MPA.0000000000000708","article-title":"Pancreatic neuroendocrine tumor abnormally secreting procalcitonin.","volume":"46","author":"Hagiya","year":"2017","journal-title":"Pancreas"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1002\/ccr3.3187","article-title":"Case of an abnormal procalcitonin-producing metastatic pancreatic neuroendocrine tumor.","volume":"8","author":"Wang","year":"2020","journal-title":"Clin Case Rep"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s10156-011-0254-x","article-title":"Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome.","volume":"17","author":"Shozushima","year":"2011","journal-title":"J Infect Chemother"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40560-019-0374-4","article-title":"Diagnostic value of procalcitonin and presepsin for sepsis in critically ill adult patients: a systematic review and meta-analysis.","volume":"7","author":"Kondo","year":"2019","journal-title":"J Intensive Care"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3343\/alm.2014.34.4.263","article-title":"Update on procalcitonin measurements.","volume":"34","author":"Meisner","year":"2014","journal-title":"Ann Lab Med"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1128\/JCM.00604-16","article-title":"Laboratory diagnosis of infections in cancer patients: challenges and opportunities.","volume":"54","author":"Babady","year":"2016","journal-title":"J Clin Microbiol"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"e0130999","DOI":"10.1371\/journal.pone.0130999","article-title":"Role of procalcitonin and interleukin-6 in predicting cancer, and its progression independent of infection.","volume":"10","author":"Chaftari","year":"2015","journal-title":"PLoS One"},{"key":"R22-20250527","first-page":"469","article-title":"Utility of blood procalcitonin concentration in the management of cancer patients with infections.","volume":"9","author":"Durna\u015b","year":"2016","journal-title":"Onco Targets Ther"},{"key":"R23-20250527","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1007\/s00432-022-04419-x","article-title":"The utility of procalcitonin for diagnosing bacteremia and bacterial pneumonia in hospitalized oncology patients.","volume":"149","author":"Munsell","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"R24-20250527","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00432-009-0699-9","article-title":"Procalcitonin as a predictive marker of infections in chemoinduced neutropenia.","volume":"136","author":"Carnino","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"R25-20250527","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.clinbiochem.2006.10.027","article-title":"Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis.","volume":"40","author":"Matzaraki","year":"2007","journal-title":"Clin Biochem"},{"key":"R26-20250527","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/ijc.32339","article-title":"Overuse of antianaerobic drug is associated with poor postchemotherapy prognosis of patients with hepatocellular carcinoma.","volume":"145","author":"Iida","year":"2019","journal-title":"Int J Cancer"},{"key":"R27-20250527","doi-asserted-by":"crossref","first-page":"S309","DOI":"10.21037\/atm.2019.10.27","article-title":"Gut microbiome, antibiotic use, and immunotherapy responsiveness in cancer.","volume":"7","author":"Reed","year":"2019","journal-title":"Ann Transl Med"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/1871526515666150320162950","article-title":"Lung cancer may increase serum procalcitonin level.","volume":"15","author":"Avrillon","year":"2015","journal-title":"Infect Disord Drug Targets"},{"key":"R29-20250527","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clinbiochem.2014.09.002","article-title":"Diagnostic and prognostic value of serum procalcitonin concentrations in primary lung cancers.","volume":"47","author":"Patout","year":"2014","journal-title":"Clin Biochem"},{"key":"R30-20250527","doi-asserted-by":"crossref","first-page":"43","DOI":"10.21037\/tlcr-21-838","article-title":"Prognostic significance of procalcitonin in small cell lung cancer.","volume":"11","author":"Ichikawa","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"R31-20250527","first-page":"3634","article-title":"Procalcitonin as an alternative tumor marker of medullary thyroid carcinoma.","volume":"106","author":"Giovanella","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R32-20250527","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00024382-200302000-00017","article-title":"Induction of procalcitonin and proinflammatory cytokines in an anhepatic baboon endotoxin shock model.","volume":"19","author":"Meisner","year":"2003","journal-title":"Shock"},{"key":"R33-20250527","first-page":"e6587","article-title":"Intrahepatic cholangiocarcinoma associated with high procalcitonin, hypercalcemia, polycythemia and leukocytosis.","volume":"12","author":"Meegada","year":"2020","journal-title":"Cureus"},{"key":"R34-20250527","doi-asserted-by":"crossref","first-page":"1191646","DOI":"10.3389\/fonc.2023.1191646","article-title":"An unresectable and metastatic intrahepatic cholangiocarcinoma with EML4-ALK rearrangement achieving partial response after first-line treatment with ensartinib: a case report.","volume":"13","author":"Huang","year":"2023","journal-title":"Front Oncol"},{"key":"R35-20250527","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12879-020-05684-2","article-title":"Continuous elevation of procalcitonin in cirrhosis combined with hepatic carcinoma: a case report.","volume":"21","author":"Lu","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R36-20250527","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/14397595.2017.1408755","article-title":"Clinical significance of plasma presepsin levels in patients with systemic lupus erythematosus.","volume":"28","author":"Tanimura","year":"2018","journal-title":"Mod Rheumatol"},{"key":"R37-20250527","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1038\/s41598-022-09926-y","article-title":"Presepsin production in monocyte\/macrophage-mediated phagocytosis of neutrophil extracellular traps.","volume":"12","author":"Ikegame","year":"2022","journal-title":"Sci Rep"},{"key":"R38-20250527","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cca.2018.09.013","article-title":"Comparison of accuracy of presepsin and procalcitonin concentrations in diagnosing sepsis in patients with and without acute kidney injury.","volume":"490","author":"Nakamura","year":"2019","journal-title":"Clin Chim Acta"},{"key":"R39-20250527","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1038\/s41598-019-41291-1","article-title":"Association between acute kidney injury and serum procalcitonin levels and their diagnostic usefulness in critically ill patients.","volume":"9","author":"Chun","year":"2019","journal-title":"Sci Rep"},{"key":"R40-20250527","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00000658-199803000-00012","article-title":"Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker.","volume":"227","author":"Goydos","year":"1998","journal-title":"Ann Surg"},{"key":"R41-20250527","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1186\/s12879-019-4618-7","article-title":"Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions.","volume":"19","author":"Song","year":"2019","journal-title":"BMC Infect Dis"},{"key":"R42-20250527","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.","volume":"60","author":"Bridgewater","year":"2014","journal-title":"J Hepatol"},{"key":"R43-20250527","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/hep.20966","article-title":"Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells.","volume":"42","author":"Isomoto","year":"2005","journal-title":"Hepatology"},{"key":"R44-20250527","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1053\/j.gastro.2006.10.037","article-title":"Sustained IL-6\/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing.","volume":"132","author":"Isomoto","year":"2007","journal-title":"Gastroenterology"},{"key":"R45-20250527","first-page":"30","article-title":"Cholangiocarcinoma tumor microenvironment highlighting fibrosis and matrix components.","volume":"9","author":"Caligiuri","year":"2023","journal-title":"Hepatoma Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:01:27Z","timestamp":1748304087000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":45,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042115","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]}}}